GE HealthCare Technologies Inc. (BVMF:GEHC34)
| Market Cap | 216.93B +25.9% |
| Revenue (ttm) | 112.08B +6.9% |
| Net Income | 11.15B -2.8% |
| EPS | 3.52 -2.1% |
| Shares Out | n/a |
| PE Ratio | 17.24 |
| Forward PE | 15.10 |
| Dividend | 0.07 (0.11%) |
| Ex-Dividend Date | Oct 22, 2026 |
| Volume | 5 |
| Open | 60.38 |
| Previous Close | n/a |
| Day's Range | 60.38 - 60.66 |
| 52-Week Range | 37.98 - 60.66 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About BVMF:GEHC34
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, an... [Read more]
Financial Performance
In 2025, BVMF:GEHC34's revenue was $20.63 billion, an increase of 4.84% compared to the previous year's $19.67 billion. Earnings were $2.08 billion, an increase of 4.57%.
Financial numbers in USD Financial StatementsNews
GE HealthCare Foundation announces 2026 grants to expand maternal and pediatric care in underserved communities
CHICAGO--(BUSINESS WIRE)--The GE HealthCare Foundation today announced its 2026 cohort of grant recipients, supporting organizations whose work will help expand access to lifesaving care for mothers a...
GE HealthCare announces new capabilities for Imaging 360
GE HealthCare (GEHC) announced two new capabilities for Imaging 360, AI assistant and AI-assisted protocoling. The Imaging 360 AI assistant and AI-assist protocoling are designed to help imaging teams...
GE HealthCare introduces new Imaging 360 features to simplify protocol management and support radiology workflows
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced two new capabilities for Imaging 360, AI assistant and AI-assisted protocoling. The Imaging 360 AI assistant and AI-assist protoc...
GE HealthCare announces Phase 2 results met primary endpoint, support Phase 3
GE HealthCare (GEHC) announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is ...
GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial
CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangacicl...
GE HealthCare integrates AW ONE ecosystem with InteleViewer
GE HealthCare (GEHC) announced the integration of the AW ONE ecosystem, a unified ecosystem for post processing and advanced visualization, with InteleViewer, IntelePACS’ diagnostic viewer designed to...
GE HealthCare brings advanced visualization into InteleViewer to support radiology workflows
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced the integration of the AW ONE ecosystem, a unified ecosystem for post processing and advanced visualization, with InteleViewer, InteleP...
GE HealthCare price target raised to $91 from $83 at BTIG
BTIG raised the firm’s price target on GE HealthCare (GEHC) to $91 from $83 and keeps a Buy rating on the shares. The firm is updating its models in Medical…
GE HealthCare receives 510(k) clearance for Critical Care Suite 3.0
GE HealthCare (GEHC) has received 510(k) clearance from the United States Food and Drug Administration for Critical Care Suite 3.0, an AI-enabled software designed to automatically detect feeding tube...
GE HealthCare announces expansion of global clinical, research collaborations
GE HealthCare (GEHC) announced an expansion of its global clinical and research collaborations to advance Photonova Spectra, the company’s next-generation photon-counting CT system. Following recent g...
GE HealthCare expands global collaborations to help define the future of photon-counting CT with Photonova™ Spectra
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an expansion of its global clinical and research collaborations to advance Photonova Spectra,i the company's next-generation phot...
GE HealthCare price target raised to $110 from $85 at Argus
Argus raised the firm’s price target on GE HealthCare (GEHC) to $110 from $85 and keeps a Buy rating on the shares. The company’s recent results have been strong, and…
GE HealthCare announces intent to establish MAGNUS Neuro Alliance
GE HealthCare (GEHC) announced the intent to establish a collaborative research network focused on advancing neuroscience research leveraging an ultra high-gradient head-only 3.0T MR system. The MAGNU...
GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the intent to establish a collaborative research network focused on advancing neuroscience research leveraging an ultra high-grad...
GE HealthCare announces two new AI-assisted capabilities for Vscan Air
GE HealthCare (GEHC) announced two new AI-assisted capabilities for its Vscan Air handheld ultrasound system: Lung Guidance and AutoAS. These are intended to support consistent lung ultrasound image a...
GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced two new AI-assisted capabilities for its Vscan Air™ handheld ultrasound system: Lung Guidance and AutoAS.1 Designed for clinician...
GE HealthCare price target raised to $80 from $73 at UBS
UBS raised the firm’s price target on GE HealthCare (GEHC) to $80 from $73 and keeps a Neutral rating on the shares. GE HealthCare posted “good” progress in Q3, but…
GE HealthCare introduces Allia Celeo, an image guiding system
GE HealthCare (GEHC) introduced Allia Celeo, a ceiling-mounted image guiding system, at the Transcatheter Cardiovascular Therapeutics, TCT, 2026 conference in San Diego. Developed around the principle...
GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today introduced Allia™ Celeo,* a ceiling-mounted image guiding system, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in...
GE HealthCare price target raised to $90 from $80 at RBC Capital
RBC Capital analyst Shagun Singh raised the firm’s price target on GE HealthCare (GEHC) to $90 from $80 and keeps an Outperform rating on the shares. The company’s 6.2% organic…
GE HealthCare price target raised to $80 from $70 at JPMorgan
JPMorgan raised the firm’s price target on GE HealthCare (GEHC) to $80 from $70 and keeps a Neutral rating on the shares.
GE HealthCare price target raised to $90 from $85 at Mizuho
Mizuho raised the firm’s price target on GE HealthCare (GEHC) to $90 from $85 and keeps an Outperform rating on the shares.
GE HealthCare price target raised to $79 from $71 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on GE HealthCare (GEHC) to $79 from $71 and keeps a Neutral rating on the shares.
GE HealthCare price target raised to $84 from $74 at BofA
BofA raised the firm’s price target on GE HealthCare (GEHC) to $84 from $74 and keeps a Neutral rating on the shares, citing both higher peer multiples and better order…
GE HealthCare price target raised to $95 from $85 at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on GE HealthCare (GEHC) to $95 from $85 and keeps an Overweight rating on the shares post the Q3 report. The…